Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

• Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company "HitGen" to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program
• Aims to strengthen its oncology portfolio with a novel drug candidate for newly identified hits from HitGen's proprietary DEL that are expected to exhibit potent anticancer activity

CHENGDU, China, Aug. 22, 2024 /PRNewswire/ -- Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen's DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.